Novel Bispecific Molecules For Use In Therapy And Diagnosis

• US 20070274998A1
• Filed: 04/29/2003
• Published: 11/29/2007
• Est. Priority Date: 04/29/2002
• Status: Abandoned Application

• Current Assignee: GenPat77 Pharmacogenetics AG (Cellact Pharma GMBH)
• Original Assignee: Genpatzz Pharmacogentetics AG
• Inventors: Utku, Nalan
• Application Number:
  US10/512,960
• Publication Number:
  US 20070274998A1
• Time in Patent Office: Days
• US Class Current: 424/173.100
• CPC Class Codes: A61K 2039/505 comprising antibodies
• CPC Class Codes: A61P 17/02 for treating wounds, ulcers, burns, scars, keloids, or the like
• CPC Class Codes: A61P 3/10 for hyperglycaemia, e.g. antidiabetics
• CPC Class Codes: A61P 31/00 Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 37/00 Drugs for immunological or allergic disorders
• CPC Class Codes: A61P 37/02 Immunomodulators
• CPC Class Codes: A61P 37/06 Immunosuppressants, e.g. drugs for graft rejection
• CPC Class Codes: A61P 37/08 Antiallergic agents antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14
• CPC Class Codes: C07K 16/28 against receptors, cell surface antigens or cell surface determinants
• CPC Class Codes: C07K 16/2809 against the T-cell receptor (TcR)-CD3 complex
• CPC Class Codes: C07K 2317/31 multispecific

Abstract

Provided are bispecific molecules that are characterized by having at least a first binding domain which binds T-cell immune response cDNA 7 (TIRC7) and a second binding domain which binds T cell receptor (TCR), in particular TCR beta or gamma chain. Furthermore, compositions comprising said bispecific molecules and their use in methods of diagnosis and treating immune response related diseases are described.

Claims

1. A bispecific molecule that comprises a first binding domain which binds T-cell immune response cDNA 7 (TIRC7) and a second binding domain which binds T cell receptor (TCR).

2. The bispecific molecule of claim 1, wherein said TCR is beta-TCR or gamma-TCR.

3. The bispecific molecule of claim 1 which is a single chain or a dimeric or multimeric molecule.

4. The bispecific molecule of claim 1 which has at least one further functional domain.

5. The bispecific molecule of claim 1 which is a bispecific antibody.

6. A nucleic acid molecule or a composition of nucleic acid molecules encoding the bispecific molecule of claim 1.

7. The nucleic acid molecule or composition of claim 6, wherein any one of said nucleic acid molecules is operably linked to expression control sequences.

8. A cell transformed with the nucleic acid molecule or composition of claim 6.

9. A method for producing a bispecific molecule of claim 1 comprising cross-linking a first binding domain which binds TIRC7 and a second binding domain which binds T cell receptor (TCR).

10. A method for producing a bispecific molecule comprising culturing the cell of claim 8 under appropriate conditions and isolating the bispecific molecule or portions thereof.

11. A composition comprising in one or more compartments, the bispecific molecule of claim 1 and optionally a pharmaceutically acceptable carrier.

12. The composition of claim 11 for use in diagnosis, prophylaxis, vaccination or therapy.

13. The use of the bispecific molecule of claim 1 for the preparation of a pharmaceutical composition for the treatment of diseases related to a disorder of the immune response, preferably for the treatment of graft versus host disease, autoimmune diseases, allergic diseases, infectious diseases, sepsis, diabetes, for the treatment of tumors, for the improvement of wound healing or for inducing or maintaining immune unresponsiveness in a subject.

14. A method of treating a mammal having an undesirable condition associated with a disease comprising administering to the mammal a therapeutically effective dose of bispecific molecules of claim 1.